Alzheimer's Care

Cannabis-based drugs have the potential to improve the lives of millions with Alzheimer’s Disease

Alleviating the Debilitating Symptoms
of Alzheimer’s

Our drug candidate, IGC-AD1, has shown promising results in treating agitation for Alzheimer’s patients with dementia.  

What We Do is Important

With no known cure, our formulations have the potential to change lives


Americans with
Disease in 2022


Americans with
Alzheimer’s Disease
by 2060

5th Leading

Cause of death among
Americans age 65+

$ 0

expected cost of Alzheimer’s and dementia by 2050 if no treatment or cure is found

Click Here
Click Here
Click Here
Click Here
Click Here
Click Here

What We Do
is Unique

Scroll Down

60-70% of Alzheimer’s patients suffer from debilitating symptoms, including agitation, anxiety, and depression.


There are no FDA-approved
drugs to treat the symptoms
of dementia
for Alzheimer’s patients.


In 2022, only 6.9% of drugs
in clinical trials
were designed to treat the symptoms of Alzheimer’s.
IGC-AD1 is the only
cannabis-based drug
in clinical trials.  


IGC-AD1 pre-clinical
studies showed
promise to treat agitation
and modify the progression of Alzheimer’s.


IGC-AD1 is the first drug that contains natural THC
to be tested on Alzheimer’s
patients in human trials.


IGC-AD1 contains ultra-low
doses of THC which minimizes safety risks and side effects.

Major Milestones


Development of cannabis-based formulations for neurological disorders such as Alzheimer’s Disease, Epilepsy, and Tourette Syndrome began


We successfully acquired the patent fillings for IGC-AD1 pre-clinical studies

which we acquired from the University of South Florida to begin working on a liquid form of the drug.


We completed a Phase 1
clinical study on our patented formulation (IGC-AD1)

to evaluate its safety and tolerability in participants with mild to severe Alzheimer’s Disease.


We acquired a small NMI-derived molecule from Jawarlal Nehru Center for Advanced Studies (JNCSR), which was efficacious against phosphorylated tau in pre-clinical studies.

We launched a Phase 2 double-blind, multi-site, randomized trial

to evaluate the efficacy of IGC-AD1 on agitation due to dementia from Alzheimer’s.